HASHKEY GLOBAL PARTNERS WITH VERIFYVASP TO EXPAND GLOBAL TRAVEL RULE COMPLIANCE
Strategic partnership strengthens regulatory compliance across HashKey Global’s international exchange network. SINGAPORE, March 9, 2025 /PRNewswire/ —... Read more.
Moments That Matter: Insights from Three Million Minutes of Caregiver Support on Trualta’s Platform
Improving outcomes for aging and high-need populations KANSAS CITY, Mo., March 9, 2025 /PRNewswire/ — Trualta, the leading learning and support platform... Read more.
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 9, 2025 /PRNewswire/ — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing... Read more.
Kaname Capital Announces Further Opposition to PROTO Corporation MBO and Introduces Statement by Former Employee
TOKYO–(BUSINESS WIRE)–Kaname Capital (“We,” “Our,” “Us”) submitted an open letter on February 18th with eight questions of concern regarding... Read more.
China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award
HONG KONG, March 7, 2025 /PRNewswire/ — On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed... Read more.
Parade Technologies Acquires Spectra7 Majority Assets to Enhance High-Speed Data Transmission Capabilities and Boost Connectivity Market Opportunities
SAN JOSE, Calif.–(BUSINESS WIRE)–Parade Technologies, Ltd. (TPEx: 4966.TWO), a leading supplier of video display, touch controller, and high-speed interface... Read more.
Faraday Future Holds Special Meeting of Stockholders, Securing Stockholder Support for All Proposals
Authorized share increase approval supports the FX strategy and continued deliveries of the FF 91 2.0. Company stock ticker to officially change to “FFAI” starting... Read more.
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive... Read more.
LDRA Announces Immediate Support for MISRA C:2025 to Facilitate Compliance for Safety- and Security-Critical Systems
LDRA tool suite automates the tracking and analysis of MISRA C guidelines in complex systems to help OEMs avoid potential software vulnerabilities, create higher... Read more.
OnPoint AR-AI to present at the 2025 Canaccord Genuity Musculoskeletal Conference
BOSTON, March 9, 2025 /PRNewswire/ — OnPoint AR-AI, a group of privately held augmented reality (AR) technology companies pioneering AR guidance and machine... Read more.